Skip to content

{ Tag Archives } Mutation

Plexxikon Announces First Patient Dosed In Phase 3 Trial Of PLX4032 (RG7204) For Metastatic Melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas [...]

Bookmark and Share Also tagged , , , , , , , ,
2010 01 11 Skin Care News Comments Off

New Study Ushers In Spring-Time For Slow Inactivation

The December 2009 issue of the Journal of General Physiology (JGP) contains a paper by Christopher Ahern (The University of British Columbia, Vancouver) and colleagues that explores pore mutation effects in Shaker and other K+ channels using in vivo nonsense suppression technology. The study was published online November 16 (http://www.jgp.org).

Bookmark and Share Also tagged , , , , , , , , , , , , ,
2009 11 18 Skin Care News Comments Off